WYMLY
TENOFOVIR ALAFENAMIDE · by GENIX
Composition
Tab 25mg: Tenofovir alafenamide (as fumarate) 25mg
Indications & Dosage
Chronic hepatitis B infection: Adult & Children above 12yrs: 25 mg once daily.
Precautions
When treating chronic hepatitis B with tenofovir, monitor liver function tests every 3 months and viral markers for hepatitis B every 3-6 months during treatment (continue monitoring for at least 1 year after discontinuation; recurrent hepatitis may occur on discontinuation), renal or hepatic impairment, hyperphosphataemia. Monitor renal function before treatment, every 4 weeks during first year, then every 3 months; reduce dose or interrupt therapy if serum phosphate or creatinine clearance is decreased. Caution in patients (particularly obese women) with hepatomegaly, hepatitis or other risk factors for liver disease and hepatic steatosis; monitor for lactic acidosis, discontinue therapy if occurs.
Interactions
Drugs that inhibit P-gp and BCRP, anticonvulsants (e.g. carbamazepine, oxcarbazepine, phenobarbital and phenytoin), antimycobacterials (e.g. rifampicin, rifabutin and rifapentine) or St. Johns wort, drugs that reduce renal function or compete for active tubular secretion, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs.
Pregnancy
Caution advised, avoid
Lactation
Caution advised, avoid
Side Effects
Headache, dizziness, rash, pruritus, increased ALT, arthralgia, diarrhea, vomiting, nausea, abdominal pain, abdominal distension, flatulence, fatigue and cough